Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HER2Bi-armed activated T cells (Barbara Ann Karmanos Cancer Institute)
- Development stage
- Unknown
- Lead developer
- Barbara Ann Karmanos Cancer Institute
- Modality
- Cell Therapies, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HER2Bi-armed activated T cells (HER2 BATs) are an autologous cell-based immunotherapy developed by the Barbara Ann Karmanos Cancer Institute in collaboration with the University of Virginia. The therapy is produced by collecting a patient's peripheral blood mononuclear cells, which are then activated with OKT3 and expanded ex vivo using IL-2. These activated T cells are subsequently "armed" with a bispecific antibody (HER2Bi) that targets both the CD3 receptor on T cells and the Human Epidermal Growth Factor Receptor 2 (HER2) on tumor cells. This mechanism allows the T cells to specifically recognize and eliminate HER2-expressing cancer cells without requiring genetic modification of the T cells. HER2 BATs are currently being investigated in Phase II clinical trials for the treatment of metastatic castration-resistant prostate cancer (mCRPC), frequently in combination with the PD-1 inhibitor pembrolizumab to overcome immune suppression in the tumor microenvironment.
- Other names
- HER2Bi-armed activated T cellsHER-2Bi-armed activated T cellsHER 2Bi-armed activated T cellsanti-CD3 x anti-HER2 bispecific antibody armed activated T cellsanti-CD-3 x anti-HER2 bispecific antibody armed activated T cellsanti-CD 3 x anti-HER2 bispecific antibody armed activated T cells
02
Targets
CD3 (T-cell surface glycoprotein CD3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on HER2Bi-armed activated T cells (Barbara Ann Karmanos Cancer Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HER2Bi-armed activated T cells (Barbara Ann Karmanos Cancer Institute).